Daiichi Sankyo Company, Limited (DSKYF)
OTCMKTS
· Delayed Price · Currency is USD
23.55
-0.75 (-3.09%)
May 12, 2025, 2:46 PM EDT
Daiichi Sankyo Company Revenue
In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T JPY with 17.77% growth. Daiichi Sankyo Company had revenue of 518.69B in the quarter ending March 31, 2025, with 21.07% growth.
Revenue
1,886.26B JPY
Revenue Growth
+17.77%
P/S Ratio
3.26
Revenue / Employee
100.73M JPY
Employees
18,726
Market Cap
41.07B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
| Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
| Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
| Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Daiichi Sankyo Company News
- 6 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 - Benzinga
- 6 days ago - ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial - Benzinga
- 15 days ago - Approaching the business with a 'patient-centric mindset': Daiichi Sankyo CEO - CNBC
- 17 days ago - Daiichi Sankyo Company, Limited (DSKYF) FY2024 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Daiichi Sankyo rises on share buyback plan - Seeking Alpha
- 18 days ago - Daiichi Sankyo repors FY results - Seeking Alpha
- 22 days ago - ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 4 weeks ago - Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha